PURPOSE: We assessed the prognostic value of systemic immune-inflammation index (SII) to refine risk stratification of the heterogeneous spectrum of patients with non-muscle-invasive bladder cancer (NMIBC) METHODS: In this multi-institutional cohort, preoperative blood-based SII was retrospectively assessed in 1117 patients with NMIBC who underwent transurethral resection of bladder (TURB) between 1996 and 2007. The optimal cut-off value of SII was determined as 580 using the best Youden index. Cox regression analyses were performed. The concordance index (C-index) and decision curve analysis (DCA) were used to assess the discrimination of the predictive models. RESULTS: Overall, 309 (28%) patients had high SII. On multivariable analyses, high SII was significantly associated with worse PFS (hazard ratio [HR] 1.84; 95% confidence interval [CI] 1.23-2.77; P = 0.003) and CSS (HR 2.53; 95% CI 1.42-4.48; P = 0.001). Subgroup analyses, according to the European Association of Urology guidelines, demonstrated the main prognostic impact of high SII, with regards to PFS (HR 3.39; 95%CI 1.57-7.31; P = 0.002) and CSS (HR 4.93; 95% CI 1.70-14.3; P = 0.005), in patients with intermediate-risk group; addition of SII to the standard predictive model improved its discrimination ability both on C-index (6% and 12%, respectively) and DCA. In exploratory intergroup analyses of patients with intermediate-risk, the improved discrimination ability was retained the prediction of PFS and CSS. CONCLUSION: Preoperative SII seems to identify NMIBC patients who have a worse disease and prognosis. Such easily available and cheap standard biomarkers may help refine the decision-making process regarding adjuvant treatment in patients with intermediate-risk NMIBC.

Department of Urology 2nd Faculty of Medicine Charles University Prague Czech Republic

Department of Urology Dentistry and Pharmaceutical Sciences Okayama University Graduate School of Medicine Okayama Japan

Department of Urology King Fahad Specialist Hospital Dammam Saudi Arabia

Department of Urology Landesklinikum Wiener Neustadt Vienna Austria

Department of Urology Luzerner Kantonsspital Luzern Switzerland

Department of Urology Medical University of Silesia 41 800 Zabrze Poland

Department of Urology Medical University of Vienna Währinger Gürtel 18 20 1090 Vienna Austria

Department of Urology Rennes University Hospital 2 Rue Henri le Guilloux 35000 Rennes France

Department of Urology The Jikei University School of Medicine Tokyo Japan

Department of Urology University Hospital Zurich Zurich Switzerland

Department of Urology University Medical Center Hamburg Eppendorf Hamburg Germany

Department of Urology University of Texas Southwestern Medical Center Dallas TX USA

Department of Urology Weill Cornell Medical College New York NY USA

Division of Urology Department of Special Surgery The University of Jordan Amman Jordan

Institute for Urology and Reproductive Health Sechenov University Moscow Russia

Karl Landsteiner Institute of Urology and Andrology Vienna Austria

Men's Health and Reproductive Health Research Center Shahid Beheshti University of Medical Sciences Tehran Iran

Research Center for Evidence Based Medicine Tabriz University of Medical Sciences Tabriz Iran

Zobrazit více v PubMed

Babjuk M, et al. European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and Carcinoma In Situ)-2019 update. Eur Urol. 2019;76(5):639–657. doi: 10.1016/j.eururo.2019.08.016. PubMed DOI

Xylinas E, et al. Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder. Br J Cancer. 2013;109(6):1460–1466. doi: 10.1038/bjc.2013.372. PubMed DOI PMC

Sylvester RJ, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49(3):466–477. doi: 10.1016/j.eururo.2005.12.031. PubMed DOI

D'Andrea D, et al. Progressive tissue biomarker profiling in non-muscle-invasive bladder cancer. Expert Rev Anticancer Ther. 2018;18(7):695–703. doi: 10.1080/14737140.2018.1474104. PubMed DOI

Soria F, et al. Diagnostic, prognostic and surveillance urinary markers in nonmuscle invasive bladder cancer: any role in clinical practice? Curr Opin Urol. 2018;28(6):577–583. doi: 10.1097/MOU.0000000000000545. PubMed DOI

Shariat SF, et al. Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer. J Urol. 2010;183(1):68–75. doi: 10.1016/j.juro.2009.08.115. PubMed DOI

Laukhtina E et al (2020) Association of De Ritis ratio with oncological outcomes in patients with non-muscle invasive bladder cancer (NMIBC). World J Urol. 10.1007/s00345-020-03384-9. Online ahead of print PubMed PMC

Quhal F et al (2021) Prognostic value of albumin to globulin ratio in non-muscle-invasive bladder cancer. World J Urol. 10.1007/s00345-020-03586-1. Online ahead of print PubMed PMC

Mbeutcha A, et al. Prognostic significance of markers of systemic inflammatory response in patients with non-muscle-invasive bladder cancer. Urol Oncol. 2016;34(11):483.e17–483.e24. doi: 10.1016/j.urolonc.2016.05.013. PubMed DOI

Yang R, et al. Prognostic value of systemic immune-inflammation index in cancer: a meta-analysis. J Cancer. 2018;9(18):3295–3302. doi: 10.7150/jca.25691. PubMed DOI PMC

Zhong JH, Huang DH, Chen ZY. Prognostic role of systemic immune-inflammation index in solid tumors: a systematic review and meta-analysis. Oncotarget. 2017;8(43):75381–75388. doi: 10.18632/oncotarget.18856. PubMed DOI PMC

Akan S, et al. Can the systemic immune inflammation index be a predictor of BCG response in patients with high-risk non-muscle invasive bladder cancer? Int J Clin Pract. 2020;75(4):e13813. PubMed

Bi H, et al. Predictive values of preoperative prognostic nutritional index and systemic immune-inflammation index for long-term survival in high-risk non-muscle-invasive bladder cancer patients: a single-centre retrospective study. Cancer Manag Res. 2020;12:9471–9483. doi: 10.2147/CMAR.S259117. PubMed DOI PMC

Mantovani A, et al. Cancer-related inflammation. Nature. 2008;454(7203):436–444. doi: 10.1038/nature07205. PubMed DOI

Soukup V, et al. Risk stratification tools and prognostic models in non-muscle-invasive bladder cancer: a critical assessment from the European association of urology non-muscle-invasive bladder cancer guidelines panel. Eur Urol Focus. 2020;6(3):479–489. doi: 10.1016/j.euf.2018.11.005. PubMed DOI

Sylvester RJ, et al. European Association of Urology (EAU) prognostic factor risk groups for non-muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC guidelines panel. Eur Urol. 2021;79(4):480–488. doi: 10.1016/j.eururo.2020.12.033. PubMed DOI

Kamat AM, et al. Defining and treating the spectrum of intermediate risk nonmuscle invasive bladder cancer. J Urol. 2014;192(2):305–315. doi: 10.1016/j.juro.2014.02.2573. PubMed DOI PMC

Soria F, et al. Stratification of intermediate-risk non-muscle-invasive bladder cancer patients: implications for adjuvant therapies. Eur Urol Focus. 2020 doi: 10.1016/j.euf.2020.05.004. PubMed DOI

Candido J, Hagemann T. Cancer-related inflammation. J Clin Immunol. 2013;33(Suppl 1):S79–84. doi: 10.1007/s10875-012-9847-0. PubMed DOI

Soria F, et al. Molecular markers in bladder cancer. World J Urol. 2019;37(1):31–40. doi: 10.1007/s00345-018-2503-4. PubMed DOI PMC

Mollinedo F. Neutrophil degranulation, plasticity, and cancer metastasis. Trends Immunol. 2019;40(3):228–242. doi: 10.1016/j.it.2019.01.006. PubMed DOI

Giese MA, Hind LE, Huttenlocher A. Neutrophil plasticity in the tumor microenvironment. Blood. 2019;133(20):2159–2167. doi: 10.1182/blood-2018-11-844548. PubMed DOI PMC

Ménétrier-Caux C, et al. Lymphopenia in cancer patients and its effects on response to immunotherapy: an opportunity for combination with cytokines? J Immunother Cancer. 2019;7(1):85. doi: 10.1186/s40425-019-0549-5. PubMed DOI PMC

Rink M, et al. The current role of circulating biomarkers in non-muscle invasive bladder cancer. Transl Androl Urol. 2019;8(1):61–75. doi: 10.21037/tau.2018.11.05. PubMed DOI PMC

van Es N, et al. Effects of cancer on platelets. Semin Oncol. 2014;41(3):311–318. doi: 10.1053/j.seminoncol.2014.04.015. PubMed DOI

Oddens J, et al. Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol. 2013;63(3):462–472. doi: 10.1016/j.eururo.2012.10.039. PubMed DOI

Hinotsu S, et al. Maintenance therapy with bacillus Calmette-Guérin Connaught strain clearly prolongs recurrence-free survival following transurethral resection of bladder tumour for non-muscle-invasive bladder cancer. BJU Int. 2011;108(2):187–195. doi: 10.1111/j.1464-410X.2010.09891.x. PubMed DOI

Mori K, et al. Low compliance to guidelines in nonmuscle-invasive bladder carcinoma: a systematic review. Urol Oncol. 2020;38(10):774–782. doi: 10.1016/j.urolonc.2020.06.013. PubMed DOI